Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold

Needham analyst Ami Fadia has maintained their neutral stance on BIIB stock, giving a Hold rating yesterday.

Ami Fadia has given his Hold rating due to a combination of factors, including encouraging phase 2 data for litifilimab in cutaneous lupus erythematosus, where the drug significantly lowered disease activity and drove higher CLASI-70 responses versus placebo, while showing an improved safety profile relative to prior studies. Although this supports continued development and could lead to near-term stock strength, the presence of multiple emerging competitors and the early-stage nature of the program temper the risk‑reward.

In addition, while Biogen’s broad lupus program and convenient once‑monthly subcutaneous dosing provide strategic advantages, key value inflection points such as the TOPAZ-1 and TOPAZ-2 phase 3 readouts in systemic lupus erythematosus are not expected until the second half of 2026. Until more definitive efficacy and safety data are available from these late-stage trials and the competitive landscape becomes clearer, Fadia views the upside as balanced by execution and clinical risks, supporting a neutral Hold stance.

In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $190.00 price target.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year.